A Phase II Study to Determine the Efficacy and Safety of Allogeneic Human Chondrocytes Expressing TGF-beta 1 (TissueGene-C) in Patients With Grade 3 Chronic Degenerative Joint Disease of the Knee

Trial Profile

A Phase II Study to Determine the Efficacy and Safety of Allogeneic Human Chondrocytes Expressing TGF-beta 1 (TissueGene-C) in Patients With Grade 3 Chronic Degenerative Joint Disease of the Knee

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs Tonogenchoncel-L (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors TissueGene
  • Most Recent Events

    • 11 May 2015 According to a TissueGene media release, data from this study were presented at the 12th World Congress of the International Cartilage Repair Society (ICRS) 2015.
    • 11 May 2015 According to a TissueGene media release, data from this study were presented at the 18th meeting of the American Society of Gene & Cell Therapy (ASGCT) 2015.
    • 13 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top